The invention relates to a process for the oxidation of santalene to santalol. The starting material is in particular a mixture comprising alpha-santalene, beta-santalene, epi-beta-santalene, trans-alpha-bergamotene and beta-bisabolene. The oxidation of the santalenes occurs via an intermediate chloro-santalene compound. Substitution of the chloro-substituent by acetate yielded the mixture of the corresponding santalyl actates, which were hydrolyzed to yield the corresponding mixture of santalols.

The invention relates to a process for the oxidation of santalene to santalol. The starting material is in particular a mixture comprising alpha-santalene, beta-santalene, epi-beta-santalene, trans-alpha-bergamotene and beta-bisabolene. The oxidation of the santalenes occurs via an intermediate chloro-santalene compound. Substitution of the chloro-substituent by acetate yielded the mixture of the corresponding santalyl actates, which were hydrolyzed to yield the corresponding mixture of santalols.

The invention relates to a process for the oxidation of santalene to santalol. The starting material is in particular a mixture comprising alpha-santalene, beta-santalene, epi-beta-santalene, trans-alpha-bergamotene and beta-bisabolene. The oxidation of the santalenes occurs via an intermediate chloro-santalene compound. Substitution of the chloro-substituent by acetate yielded the mixture of the corresponding santalyl actates, which were hydrolyzed to yield the corresponding mixture of santalols.

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

The present invention provides a process for purifying a monoterpene or sesquiterpene having a purity greater than about 98.5% (w/w). The process comprises the steps of derivatizing the monoterpene (or sesquiterpene) to produce a monoterpene (or sesquiterpene) derivative, separating the monoterpene (or sesquiterpene) derivative, and releasing the monoterpene (or sesquiterpene) from the derivative. Also encompassed by the scope of the present invention is a pharmaceutical composition comprising a monoterpene (or sesquiterpene) having a purity greater than about 98.5% (w/w). The purified monoterpene can be used to treat a disease such as cancer. The present monoterpene (or sesquiterpene) may be administered alone, or may be co-administered with radiation or other therapeutic agents, such as chemotherapeutic agents.

The present invention relates to process for the preparation of cannabidiol (A) from the coupling of (D) and (E) through the intermediates (C) and (D) starting from compound (B). The invention further relates to the novel compounds (B), (C), (D) and (E) and reagents used in this process. More specifically, this invention provides the manufacturing of Cannabidiol (A) in milligram to gram or kilogram scale.

##STR00001##

The present invention relates to process for the preparation of cannabidiol (A) from the coupling of (D) and (E) through the intermediates (C) and (D) starting from compound (B). The invention further relates to the novel compounds (B), (C), (D) and (E) and reagents used in this process. More specifically, this invention provides the manufacturing of Cannabidiol (A) in milligram to gram or kilogram scale.

##STR00001##

The present invention provides a method for preparing 2,2-bis(4-hydroxycyclohexyl)propane, comprising: hydrogenating a reactive solution containing 2,2-bis(4-hydroxyphenyl)propane under a hydrogen atmosphere in a reactor with catalyst within a temperature range of 80-165° C. and a pressure range of 85-110 kg/cm.sup.2 to prepare the 2,2-bis(4-hydroxycyclohexyl)propane. The method of present invention has an advantage of high yield properties and achieves mass production easily, thereby enhancing the value of the industrial application.

The present invention provides a method for preparing 2,2-bis(4-hydroxycyclohexyl)propane, comprising: hydrogenating a reactive solution containing 2,2-bis(4-hydroxyphenyl)propane under a hydrogen atmosphere in a reactor with catalyst within a temperature range of 80-165° C. and a pressure range of 85-110 kg/cm.sup.2 to prepare the 2,2-bis(4-hydroxycyclohexyl)propane. The method of present invention has an advantage of high yield properties and achieves mass production easily, thereby enhancing the value of the industrial application.

A novel odorant of formula (I) wherein each of R.sub.1, R.sub.2, R.sub.3, R.sub.3, R.sub.5, R.sub.6, R.sub.7, R.sub.8, R.sub.9 and R.sub.10 are independently selected from H, CH.sub.3, and C.sub.2H.sub.5; X is selected from —CH.sub.2OH, —CH.sub.2OCOCH.sub.3 and —CHO, n is selected from 0 and 1. The dotted line represents double bond or single bond. ##STR00001##